Epidemiological studies have suggested an association between low selenium levels and the development of prostate cancer. Human cellular glutathione peroxidase I (hGPX1) is a selenium-dependent enzyme that protects against oxidative damage and its peroxidase activity is a plausible mechanism for cancer prevention by selenium. The GPX1 gene has a GCG repeat polymorphism in exon 1, coding for a polyalanine tract of five to seven alanine residues. To test if the GPX1 GCG repeat polymorphism associates with the risk of young-onset prostate cancer we conducted a case -control study. The GPX1 Ala genotypes were determined for 267 prostate cancer cases and 260 control individuals using polymerase chain reaction (PCR) amplification with fluorescently labelled primers and an ABI 377 automated genotyper. Associations between specific genotypes and the risk of prostate cancer were examined by logistic regression. We found no significant association between the GPX1 genotypes and prostate cancer. There was however an increased frequency of the GPX1 Ala6/Ala6 genotype in the prostate cancer cases compared to controls (OR: 1.67; 95% CI: 0.97 -2.87). The result of this study suggests that the GPX1 genotype is unlikely to be associated with the risk of developing prostate cancer.
Introduction
Prostate cancer is the second most common cancer in men in the UK. About 14 000 cases are diagnosed each year and it accounts for 9000 deaths annually. 1 Whilst most cases develop in elderly men, 13% of cases occur in men aged less than 65 y. Epidemiological studies have demonstrated familial aggregation of the disease that suggests genetic predisposition, particularly in younger men, to the disease.
Recent studies suggest an association between low levels of selenium and the risk of prostate cancer. Clark and colleagues 2 found striking evidence that selenium supplementation protected men against prostate cancer in a randomised trial in the USA (OR: 0.35; CI: 0.18 -0.65). Another study has revealed an inverse association between advanced prostate cancer and toe-nail selenium levels, a surrogate marker of long-term selenium intake. 3 A large case -control study however failed to find a similar association between prostate cancer risk and toenail selenium, but the selenium level was inversely correlated with colon cancer risk. 4 Two recent reports also suggested the benefit of selenium in relation to incident prostate cancer, 5, 6 however the association was mainly present in current or past cigarette smokers. 5 These findings provide some evidence for a possible protective role of selenium against the development of prostate cancer.
The human glutathione-peroxidase 1 (hGPX1) is a selenium-dependent enzyme which participates in the detoxification of activated oxygen species by catalysing reduction of these genotoxic compounds. 7 Therefore it is plausible that a genetic alteration or polymorphisms in the GPX1 gene may also have an effect on prostate cancer risk. The presence of a GCG repeat polymorphism coding for alanine residues in a polyalanine tract of GPX1 was described by Moscow et al. 8 They have also reported that other polymorphisms co-segregate with one of the alleles, a proline to leucine substitution at codon 198, a T to C substitution at þ 2 and a G for A substitution at 7 592. In a recent study it was shown that the Pro198Leu polymorphism was significantly associated with the risk of developing lung cancer in a case -control study confirming the role of GPX1 as a potent risk factor in tumour development. 9 Our aim in the present study was to investigate the relationship between the GCG repeat polymorphism in GPX1 and prostate cancer risk using a large series of early onset prostate cancer cases and controls.
Materials and methods

Study population
Blood samples were obtained from 275 Caucasian patients living in the UK, who had histologically proven prostate cancer diagnosed before the age of 56 y. Ascertainment of cases was obtained through Consultants collaborating in the CRC/BPG UK Familial Prostate Cancer Study organised by The Institute of Cancer Research and The Royal Marsden NHS Trust. Patients were not selected on the basis of their family history and only a small proportion (12%) had family history of prostate cancer. Control blood samples were obtained from 270 geographically matched individuals who were spouses of patients in a population based study of colorectal cancer. No specific age matching was carried out but the mean age of the cases was similar to the control individuals (51 y). Controls with a previous diagnosis of any cancer were excluded.
Genotyping
Polymerase chain reaction (PCR) amplifications were performed using genomic DNA extracted from the blood samples of cases and controls by standard methods. For the genotyping of the GPX1 GCG polymorphism, fluorescently labelled primers were used (sense: 5 0 -GAA ACT GCC TGT GCC ACG TGA CC-3 0 ; antisense: 5 0 -CGA GAA GGC ATA CAC CGA CTG GGC-3 0 ). Briefly, for all PCR reactions, 25 ng genomic DNA was used in a 15 ml reaction mixture. The PCR reactions contained 1.5 mM MgCl 2 , 6 pM of each primer, 0.5 U of Amplitaq Gold polymerase (The Perkin Elmer Corp. Norwalk, CT, USA). The reactions were performed with an annealing temperature of 60 C for 35 cycles in a Hybaid Touchdown PCR machine. Following PCR amplification the repeat length of the samples was analysed on 6% polyacrylamide gels using an ABI 377 automated DNA Sequencer. The size of the amplified products was determined relative to size standards using Genescan and Genotyper Analysis software (Applied Biosystem). Allele calling was done without the knowledge of case or control status.
Statistical analysis
Association between the GPX1 genotypes and the development of prostate cancer was presented in the usual way in terms of odds ratios (OR) based on logistic regression, but using 95% floating confidence limits (FCLs) rather than standard confidence intervals. In this case the analysis was performed under the restriction that the genotype frequencies in the controls and in the cases were in Hardy-Weinberg equilibrium and based significance levels on a likelihood ratio test. This approach has been shown to provide a more powerful test of a genotypic effect. 10 This sample size has approximately 80% power to detect an odds ratio of 2 for the putative high risk genotype significant at the 1% level. 
Results
The GPX1 trinucleotide polymorphism (GCG repeat) in exon 1 was genotyped successfully for 267 of the 275 prostate cancer cases and for 260 of the 270 control individuals. As shown in Figure 1 , all three alleles coding for five, six or seven alanines in the polyalanine track (Ala5, Ala6, Ala7) occur with a frequency of 49, 29 and 24% respectively and about 70% of genotypes are heterozygous in the European CEPH sample set. 6 Genotyping results are shown in Table 1 . We found no significant association between the GPX1 genotypes and the risk of young onset prostate cancer (w 2 5 ¼ 2.64; P ¼ 0.12). The Ala6 homozygous genotype had slightly higher frequency in the prostate cancer group compared to the control population (12 vs 7%), corresponding to an odds ratio of 1.67 (CI:0.97 -2.87) relative to the Ala5 homozygotes. The Ala6 allele was slightly more common overall in cases than in controls (33 vs 29%) but again the difference in allele frequencies between cases and controls was not significant (w 2 2 ¼ 1.88, P ¼ 0.39). Presently it is unknown whether this GCG repeat polymorphism has any effect on the properties of the GPX1 enzyme. Besides the difference in the length of the polyalanine track the Ala6 allele is in complete linkage disequilibrium with an amino acid substitution (Leu198Pro) in the coding region and two more base substitutions outside the coding regions. 8 Thus, this allele is the most likely to code for a functionally different protein.
Discussion
Amongst the many genetic and environmental factors that influence the risk for developing prostate cancer selenium intake is one possible candidate. So far, four studies have reported a significant reduction in risk for prostate cancer as the selenium intake increased. Two of them are based on the measurement of the long-term selenium intake using toe-nail clippings, 3, 6 one is based on serum selenium measurements, 5 and one on selenium supplementation in a double-blinded study. 2 Three studies reported a reduction of risk for developing prostate cancer as the selenium level increased, suggesting that selenium can provide a two -three-fold protection against prostate cancer. One study showed an association only in smokers, 5 and one study failed to find any significant association between toe-nail selenium level and the risk of prostate cancer. 4 How selenium might prevent prostate cancer development is a challenging question. As selenium is an important element in glutathione peroxidases (GPXs), a major antioxidant enzyme family, it is reasonable to suggest that it could have chemopreventative effect through the function of GPXs that provide protection against oxidative damage of DNA. As selenium intake seems to be an important environmental factor in the susceptibility for prostate cancer, GPX genes could be considered as candidate low penetrance prostate cancer genes.
Genetic predisposition is one important factor in the development of prostate cancer. We selected a cohort of young-onset prostate cancer cases (diagnosed at < 56 y of age) to provide a suitable study population that may have developed prostate cancer as a result of a genetic predisposition. Human cellular glutathione peroxidase I (hGPX1) is a selenium dependent antioxidant enzyme and the gene, GPX1 maps to 3p21. 6 In addition to an informative trinucleotide repeat polymorphism that has been genotyped in our study, three other common single nucleotide polymorphisms (SNPs) have been identified: a leucine to proline substitution at codon 198 (C > T at 593) and two further base changes in the non-coding region (C > T at þ 2 and G > A at 7 592). These three polymorphisms are in complete linkage disequilibrium with the Ala6 repeat, therefore this allele is the most likely to be functionally distinct. It is interesting that we found some suggestions of an elevated risk in Ala6 carriers and particularly Ala6 homozygotes (RR ¼ 1.67; 95% CI ¼ 0.97 -2.87). Furthermore, carriers of this allele were found to have a significantly elevated risk of developing lung cancer in other studies. 9 The biochemical properties of hGPX1 have been extensively studied. 11 Glutathione peroxidase I is a selenoprotein, a primary antioxidant enzyme involved in the degradation of peroxides and hydroperoxides which damage cell membranes and DNA. The enzyme is a homotetramer, each subunit is 22 kD, and contains one atom of selenium. The selenium exists in the protein as a catalytically active selenocysteine residue at amino acid 47. The protein sequence is highly conserved, except for the last five amino acids, which are quite variable. If these residues are ignored, the homology of the human GPX1 to the mouse is about 90%. The amino acids believed to be important in the function of the enzyme are all conserved in species where sequence data are available. Glu82 and Trp160 are in a hydrogen-bond to the selenocysteine selenolate; Arg52 and Arg179 are believed to form saltbridges to the carboxylate groups of glutathione. Thus, the significance of the polymorphism of the human GPX1 at the polyalanine track at codons 7 -14 and the Pro to Leu substitution at codon 198 is presently unknown.
Since hGPX1 decomposes hydrogen peroxides and organic hydroperoxides produced during normal metabolism and after oxidative stress, it prevents peroxideinduced oxidative damage, lipid peroxidation and protein degradation. Recently it has been found that GPX1 is inducible by etoposide, a topoisomerase II inhibitor, an apoptosis inducer and a TP53 activator. 12 DNA binding assays have proved that TP53 positively regulates an upstream promoter element of the GPX gene. This transactivation of GPX1 by TP53 links the TP53 signalling pathway to the antioxidant pathway. As TP53 is activated by DNA damaging agents, this finding suggests an GPX1 polymorphism and prostate cancer risk Z Kote-Jarai et al important role of antioxidant enzymes in the cellular response not only to oxidative stress but also to DNA damage. The exogenous selenium supply has been found to control the enzymatic activity of hGPX1. In a selenium deficient environment, cells have about 5% of normal hGPX1 activity. 13 However, the GPX1 mRNA level is not affected by the selenium level which suggests that the human GPX1 gene is regulated post-transcriptionally by selenium. It has also been demonstrated that selenium has a dose-dependent growth inhibition on prostate cancer cell lines 14 and this effect was not observed in normal cells. This indicates that selenium and perhaps GPX1 activity as well could have a specific effect in prostate tumorigenesis. It would be interesting to know whether the GPX1 polymorphism associates with any clinical parameters, such as survival or grade of the prostate cancer. We are currently collecting the data on the clinical and pathological characteristics of our cases, which could provide valuable information for stratification of our study population.
Based on previous studies, dietary selenium proved to be a strong candidate as an environmental factor, altering the risk for prostate cancer development. Whether the GCG polymorphism in the selenium dependent GPX1 gene alters the GPX1 antioxidant activity still remains to be seen. Our data do not show a significant association between this polymorphism and the development of young onset prostate cancer although we had a reasonable power to detect an odds ratio of 2. Based on this study it is unlikely that the GPX1 polymorphisms have a significant role in prostate cancer development and the protective effect of selenium is more likely to be mediated by another mechanism.
